Chronic hepatitis B reactivation: a word of caution regarding the use of systemic glucocorticosteroid therapy
Summary Background The potentially fatal complications associated with viral hepatitis B (HBV) reactivation have not been characterized in bullous/connective tissue disease patients receiving prolonged systemic glucocorticosteroids (GCs). Objectives This study reports HBV reactivation following GC...
Gespeichert in:
| Veröffentlicht in: | British journal of dermatology (1951) 2007-09, Vol.157 (3), p.587-590 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 590 |
|---|---|
| container_issue | 3 |
| container_start_page | 587 |
| container_title | British journal of dermatology (1951) |
| container_volume | 157 |
| creator | Yang, C-H. Wu, T-S. Chiu, C-T. |
| description | Summary
Background The potentially fatal complications associated with viral hepatitis B (HBV) reactivation have not been characterized in bullous/connective tissue disease patients receiving prolonged systemic glucocorticosteroids (GCs).
Objectives This study reports HBV reactivation following GC therapy for a case series of pemphigus vulgaris and dermatomyositis.
Methods The retrospective study cohort comprised 98 patients who received at least 6 months of systemic GC therapy.
Results Four cases of HBV carriers with viral hepatitis flare were identified. Two patients suffered fulminant hepatitis and died, while the remaining two patients experienced recurrent hepatitis flare following antiviral medication. The mean time from the start of GCs to the time of HBV reactivation was 10·5 months.
Conclusions HBV infection is an important global public health problem. Fatal HBV reactivation may occur following long‐term systemic GC therapy. Given the risk of mortality, all bullous/connective tissue disease patients should be screened for serum hepatitis B markers before commencing systemic GC therapy. |
| doi_str_mv | 10.1111/j.1365-2133.2007.08058.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68165735</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68165735</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5018-136d36fdfd97dc69b8896f88b68e1ac7874b94ef8d131d10843e7502359d8c0e3</originalsourceid><addsrcrecordid>eNqNkV2PEyEYhYnRuHX1Lxhu9G5GKMOXiRe2urua9SvR6B2hwLTUmaELM2777wXb7N7KDfCe57zAAQCIUY3zeLWtMWG0mmNC6jlCvEYCUVHvH4DZnfAQzFCWKiQZOQNPUtoihAmi6DE4w5xKhhs6A_1yE8PgDdy4nR796BNcwOi0Gf2fvA_Da6jhbYgWhhYaPZVS1tc6Wj-s4bhxcEquiOmQRtfnTutuMsGEOHoTcikGbwsX9e7wFDxqdZfcs9N8Dn5cvP--vKquv1x-WL69rgxFWFT5DZaw1rZWcmuYXAkhWSvEigmHteGCNyvZuFZYTLDFSDTEcYrmhEorDHLkHLw89t3FcDO5NKreJ-O6Tg8uTEkxgRnlhGZQHEETQ0rRtWoXfa_jQWGkStRqq0qiqiSqStTqX9Rqn63PT2dMq97Ze-Mp2wy8OAE6Gd21UQ_Gp3tOSJm_o3Bvjtyt79zhvy-gFh_flVX2V0e_z2nv7_w6_laME07Vz8-X6uvF4te3T1eNmpO_bumqLQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68165735</pqid></control><display><type>article</type><title>Chronic hepatitis B reactivation: a word of caution regarding the use of systemic glucocorticosteroid therapy</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Yang, C-H. ; Wu, T-S. ; Chiu, C-T.</creator><creatorcontrib>Yang, C-H. ; Wu, T-S. ; Chiu, C-T.</creatorcontrib><description>Summary
Background The potentially fatal complications associated with viral hepatitis B (HBV) reactivation have not been characterized in bullous/connective tissue disease patients receiving prolonged systemic glucocorticosteroids (GCs).
Objectives This study reports HBV reactivation following GC therapy for a case series of pemphigus vulgaris and dermatomyositis.
Methods The retrospective study cohort comprised 98 patients who received at least 6 months of systemic GC therapy.
Results Four cases of HBV carriers with viral hepatitis flare were identified. Two patients suffered fulminant hepatitis and died, while the remaining two patients experienced recurrent hepatitis flare following antiviral medication. The mean time from the start of GCs to the time of HBV reactivation was 10·5 months.
Conclusions HBV infection is an important global public health problem. Fatal HBV reactivation may occur following long‐term systemic GC therapy. Given the risk of mortality, all bullous/connective tissue disease patients should be screened for serum hepatitis B markers before commencing systemic GC therapy.</description><identifier>ISSN: 0007-0963</identifier><identifier>EISSN: 1365-2133</identifier><identifier>DOI: 10.1111/j.1365-2133.2007.08058.x</identifier><identifier>PMID: 17596145</identifier><identifier>CODEN: BJDEAZ</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adult ; Aged ; Biological and medical sciences ; Bullous diseases of the skin ; Cohort Studies ; Dermatology ; dermatomyositis ; Dermatomyositis - virology ; Fatal Outcome ; Female ; Glucocorticoids - administration & dosage ; Glucocorticoids - adverse effects ; glucocorticosteroid ; hepatitis B ; Hepatitis B Surface Antigens - blood ; Hepatitis B virus - drug effects ; Hepatitis B, Chronic - virology ; Human viral diseases ; Humans ; Infectious diseases ; Male ; Medical sciences ; Middle Aged ; Pemphigus - virology ; pemphigus vulgaris ; Retrospective Studies ; Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis ; Treatment Outcome ; Viral diseases ; Viral hepatitis ; Virus Activation</subject><ispartof>British journal of dermatology (1951), 2007-09, Vol.157 (3), p.587-590</ispartof><rights>2007 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5018-136d36fdfd97dc69b8896f88b68e1ac7874b94ef8d131d10843e7502359d8c0e3</citedby><cites>FETCH-LOGICAL-c5018-136d36fdfd97dc69b8896f88b68e1ac7874b94ef8d131d10843e7502359d8c0e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1365-2133.2007.08058.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1365-2133.2007.08058.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18993055$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17596145$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yang, C-H.</creatorcontrib><creatorcontrib>Wu, T-S.</creatorcontrib><creatorcontrib>Chiu, C-T.</creatorcontrib><title>Chronic hepatitis B reactivation: a word of caution regarding the use of systemic glucocorticosteroid therapy</title><title>British journal of dermatology (1951)</title><addtitle>Br J Dermatol</addtitle><description>Summary
Background The potentially fatal complications associated with viral hepatitis B (HBV) reactivation have not been characterized in bullous/connective tissue disease patients receiving prolonged systemic glucocorticosteroids (GCs).
Objectives This study reports HBV reactivation following GC therapy for a case series of pemphigus vulgaris and dermatomyositis.
Methods The retrospective study cohort comprised 98 patients who received at least 6 months of systemic GC therapy.
Results Four cases of HBV carriers with viral hepatitis flare were identified. Two patients suffered fulminant hepatitis and died, while the remaining two patients experienced recurrent hepatitis flare following antiviral medication. The mean time from the start of GCs to the time of HBV reactivation was 10·5 months.
Conclusions HBV infection is an important global public health problem. Fatal HBV reactivation may occur following long‐term systemic GC therapy. Given the risk of mortality, all bullous/connective tissue disease patients should be screened for serum hepatitis B markers before commencing systemic GC therapy.</description><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Bullous diseases of the skin</subject><subject>Cohort Studies</subject><subject>Dermatology</subject><subject>dermatomyositis</subject><subject>Dermatomyositis - virology</subject><subject>Fatal Outcome</subject><subject>Female</subject><subject>Glucocorticoids - administration & dosage</subject><subject>Glucocorticoids - adverse effects</subject><subject>glucocorticosteroid</subject><subject>hepatitis B</subject><subject>Hepatitis B Surface Antigens - blood</subject><subject>Hepatitis B virus - drug effects</subject><subject>Hepatitis B, Chronic - virology</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pemphigus - virology</subject><subject>pemphigus vulgaris</subject><subject>Retrospective Studies</subject><subject>Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis</subject><subject>Treatment Outcome</subject><subject>Viral diseases</subject><subject>Viral hepatitis</subject><subject>Virus Activation</subject><issn>0007-0963</issn><issn>1365-2133</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkV2PEyEYhYnRuHX1Lxhu9G5GKMOXiRe2urua9SvR6B2hwLTUmaELM2777wXb7N7KDfCe57zAAQCIUY3zeLWtMWG0mmNC6jlCvEYCUVHvH4DZnfAQzFCWKiQZOQNPUtoihAmi6DE4w5xKhhs6A_1yE8PgDdy4nR796BNcwOi0Gf2fvA_Da6jhbYgWhhYaPZVS1tc6Wj-s4bhxcEquiOmQRtfnTutuMsGEOHoTcikGbwsX9e7wFDxqdZfcs9N8Dn5cvP--vKquv1x-WL69rgxFWFT5DZaw1rZWcmuYXAkhWSvEigmHteGCNyvZuFZYTLDFSDTEcYrmhEorDHLkHLw89t3FcDO5NKreJ-O6Tg8uTEkxgRnlhGZQHEETQ0rRtWoXfa_jQWGkStRqq0qiqiSqStTqX9Rqn63PT2dMq97Ze-Mp2wy8OAE6Gd21UQ_Gp3tOSJm_o3Bvjtyt79zhvy-gFh_flVX2V0e_z2nv7_w6_laME07Vz8-X6uvF4te3T1eNmpO_bumqLQ</recordid><startdate>200709</startdate><enddate>200709</enddate><creator>Yang, C-H.</creator><creator>Wu, T-S.</creator><creator>Chiu, C-T.</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200709</creationdate><title>Chronic hepatitis B reactivation: a word of caution regarding the use of systemic glucocorticosteroid therapy</title><author>Yang, C-H. ; Wu, T-S. ; Chiu, C-T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5018-136d36fdfd97dc69b8896f88b68e1ac7874b94ef8d131d10843e7502359d8c0e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Bullous diseases of the skin</topic><topic>Cohort Studies</topic><topic>Dermatology</topic><topic>dermatomyositis</topic><topic>Dermatomyositis - virology</topic><topic>Fatal Outcome</topic><topic>Female</topic><topic>Glucocorticoids - administration & dosage</topic><topic>Glucocorticoids - adverse effects</topic><topic>glucocorticosteroid</topic><topic>hepatitis B</topic><topic>Hepatitis B Surface Antigens - blood</topic><topic>Hepatitis B virus - drug effects</topic><topic>Hepatitis B, Chronic - virology</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pemphigus - virology</topic><topic>pemphigus vulgaris</topic><topic>Retrospective Studies</topic><topic>Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis</topic><topic>Treatment Outcome</topic><topic>Viral diseases</topic><topic>Viral hepatitis</topic><topic>Virus Activation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yang, C-H.</creatorcontrib><creatorcontrib>Wu, T-S.</creatorcontrib><creatorcontrib>Chiu, C-T.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of dermatology (1951)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yang, C-H.</au><au>Wu, T-S.</au><au>Chiu, C-T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chronic hepatitis B reactivation: a word of caution regarding the use of systemic glucocorticosteroid therapy</atitle><jtitle>British journal of dermatology (1951)</jtitle><addtitle>Br J Dermatol</addtitle><date>2007-09</date><risdate>2007</risdate><volume>157</volume><issue>3</issue><spage>587</spage><epage>590</epage><pages>587-590</pages><issn>0007-0963</issn><eissn>1365-2133</eissn><coden>BJDEAZ</coden><abstract>Summary
Background The potentially fatal complications associated with viral hepatitis B (HBV) reactivation have not been characterized in bullous/connective tissue disease patients receiving prolonged systemic glucocorticosteroids (GCs).
Objectives This study reports HBV reactivation following GC therapy for a case series of pemphigus vulgaris and dermatomyositis.
Methods The retrospective study cohort comprised 98 patients who received at least 6 months of systemic GC therapy.
Results Four cases of HBV carriers with viral hepatitis flare were identified. Two patients suffered fulminant hepatitis and died, while the remaining two patients experienced recurrent hepatitis flare following antiviral medication. The mean time from the start of GCs to the time of HBV reactivation was 10·5 months.
Conclusions HBV infection is an important global public health problem. Fatal HBV reactivation may occur following long‐term systemic GC therapy. Given the risk of mortality, all bullous/connective tissue disease patients should be screened for serum hepatitis B markers before commencing systemic GC therapy.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>17596145</pmid><doi>10.1111/j.1365-2133.2007.08058.x</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0963 |
| ispartof | British journal of dermatology (1951), 2007-09, Vol.157 (3), p.587-590 |
| issn | 0007-0963 1365-2133 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68165735 |
| source | Oxford University Press Journals All Titles (1996-Current); MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Aged Biological and medical sciences Bullous diseases of the skin Cohort Studies Dermatology dermatomyositis Dermatomyositis - virology Fatal Outcome Female Glucocorticoids - administration & dosage Glucocorticoids - adverse effects glucocorticosteroid hepatitis B Hepatitis B Surface Antigens - blood Hepatitis B virus - drug effects Hepatitis B, Chronic - virology Human viral diseases Humans Infectious diseases Male Medical sciences Middle Aged Pemphigus - virology pemphigus vulgaris Retrospective Studies Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis Treatment Outcome Viral diseases Viral hepatitis Virus Activation |
| title | Chronic hepatitis B reactivation: a word of caution regarding the use of systemic glucocorticosteroid therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T01%3A49%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chronic%20hepatitis%20B%20reactivation:%20a%20word%20of%20caution%20regarding%20the%20use%20of%20systemic%20glucocorticosteroid%20therapy&rft.jtitle=British%20journal%20of%20dermatology%20(1951)&rft.au=Yang,%20C-H.&rft.date=2007-09&rft.volume=157&rft.issue=3&rft.spage=587&rft.epage=590&rft.pages=587-590&rft.issn=0007-0963&rft.eissn=1365-2133&rft.coden=BJDEAZ&rft_id=info:doi/10.1111/j.1365-2133.2007.08058.x&rft_dat=%3Cproquest_cross%3E68165735%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68165735&rft_id=info:pmid/17596145&rfr_iscdi=true |